相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bacterial Factors That Predict Relapse after Tuberculosis Therapy
R. Colangeli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians
Jan-Willem C. Alffenaar et al.
CLINICAL INFECTIOUS DISEASES (2017)
The challenges of pharmacokinetic variability of first-line anti-TB drugs
Bella Devaleenal Daniel et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis
Abdullah Alsultan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections
Charles Peloquin
MICROBIOLOGY SPECTRUM (2017)
Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial
Antonia M. I. Saktiawati et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in ChildrenWith Tuberculosis With and Without HIV Coinfection
Awewura Kwara et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2016)
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines
A. Bekker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
Neesha Rockwood et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid et al.
CLINICAL INFECTIOUS DISEASES (2016)
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
Marlanka A. Zuur et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status
Geetha Ramachandran et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting
Natasha van't Boveneind-Vrubleuskaya et al.
PLOS ONE (2016)
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis
Marieke G. G. Sturkenboom et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi
J. J. van Oosterhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
Aparna Mukherjee et al.
BMC INFECTIOUS DISEASES (2015)
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection
Alper Daskapan et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs: Challenges and Research Priorities for Resource-Limited Settings
Hadija H. Semvua et al.
THERAPEUTIC DRUG MONITORING (2015)
Pharmacokinetics of First-Line Antituberculosis Drugs in HIV-Infected Children with Tuberculosis Treated with Intermittent Regimens in India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
Paolo Denti et al.
PLOS ONE (2015)
Nutritional Supplementation Increases Rifampin Exposure among Tuberculosis Patients Coinfected with HIV
Kidola Jeremiah et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
Ana Requena-Mendez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug-Drug Interactions with Rifamycins
Mario Regazzi et al.
CLINICAL PHARMACOKINETICS (2014)
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Abdullah Alsultan et al.
DRUGS (2014)
Understanding pharmacokinetics to improve tuberculosis treatment outcome
Jonathan Reynolds et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS
D. H. Vu et al.
TALANTA (2014)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines
Helen McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV
Ana Requena-Mendez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Dried Blood Spot Analysis Combined With Limited Sampling Models Can Advance Therapeutic Drug Monitoring of Tuberculosis Drugs
Jan-Willem C. Alffenaar
JOURNAL OF INFECTIOUS DISEASES (2012)
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
Siv Jonsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen et al.
CLINICAL INFECTIOUS DISEASES (2011)
Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
Marc Weiner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
HIV Infection-Associated Tuberculosis: The Epidemiology and the Response
Haileyesus Getahun et al.
CLINICAL INFECTIOUS DISEASES (2010)
Effect of treating co-infections on HIV-1 viral load: a systematic review
Kayvon Modjarrad et al.
LANCET INFECTIOUS DISEASES (2010)
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
Hendrik Simon Schaaf et al.
BMC MEDICINE (2009)
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana
Sekai Chideya et al.
CLINICAL INFECTIOUS DISEASES (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Therapeutic Drug Monitoring of Nevirapine in Resource-Limited Settings
Rafaella F. A. L'homme et al.
CLINICAL INFECTIOUS DISEASES (2008)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection
SM Graham et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis
DC Perlman et al.
CLINICAL INFECTIOUS DISEASES (2005)
Isoniazid pharmacokinetics in children treated for respiratory tuberculosis
HS Schaaf et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2005)
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis
M Weiner et al.
CLINICAL INFECTIOUS DISEASES (2005)
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis
DC Perlman et al.
CLINICAL INFECTIOUS DISEASES (2004)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin
JE Conte et al.
CLINICAL PHARMACOKINETICS (2004)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy
JB Mehta et al.
CHEST (2001)
分享论文
